secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2026-07-20T12:30:05+00:00
Accession:  0001193125-26-308409
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular reports positive 2-year Phase 2b data for 4D-150 in wet AMD; 78% treatment burden reduction
--------------------------------------------------------------------------------

- Overall cohort: 78% reduction in treatment burden (2.7 mean supplemental injections vs 12.0 projected for aflibercept Q8W).
- Recently diagnosed subgroup: 87% reduction (1.6 mean supplemental injections vs 12.0).
- Dose response maintained in favor of Phase 3 dose (3E10 vg/eye) over 2 years.
- Safety: 2.8% (2/71) had transient mild IOI within first 28 weeks; no new inflammation with up to 4+ years follow-up.
- No 4D-150-related hypotony, endophthalmitis, vasculitis, or choroidal effusions observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312526308409/0001193125-26-308409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312526308409/d98747d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-308409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer